OBJECTIVES: To determine if highly active antiretroviral therapy (HAART) with combination anti-hepatitis B virus (HBV) therapy compared to HAART with HBV monotherapy leads to greater HBV DNA suppression in an HIV/HBV coinfected cohort. DESIGN: A cross-sectional analysis of 122 HIV/HBV coinfected patients from Australia and the United States. METHODS: Univariate analysis and ordinal logistic regression were used to determine factors associated with an HBV DNA less than 100 IU/ml. RESULTS: The majority of patients were on HAART (85%), had an HIV RNA less than 50 copies/ml, a median CD4 cell count of 438 cells/microl, and had prior or current lamivudine therapy (98%). The majority (89%) of those on HAART were on HBV-active drugs including 54% on tenofovir (TDF) with either lamivudine (LAM) or emtrictabine (FTC), 34% receiving LAM or FTC monotherapy, and 12% on TDF monotherapy. Only 4% of patients in the combination (TDF + LAM/FTC) group had HBV DNA greater than 20 000 IU/ml compared to 54% in the group on no HBV-active therapy, 31% in the LAM or FTC monotherapy group, and 30% in the TDF monotherapy group (P < 0.0001). In an ordinal logistic regression model, monotherapy with either TDF or LAM remained independently associated with higher HBV DNA. CONCLUSION: These data suggest that there may be an advantage to using TDF in combination with LAM or FTC in HIV/HBV coinfection, particularly in the setting of previous LAM experience. Continued prospective follow-up in this study will confirm whether the advantage is sustained longer-term.
OBJECTIVES: To determine if highly active antiretroviral therapy (HAART) with combination anti-hepatitis B virus (HBV) therapy compared to HAART with HBV monotherapy leads to greater HBV DNA suppression in an HIV/HBV coinfected cohort. DESIGN: A cross-sectional analysis of 122 HIV/HBV coinfectedpatients from Australia and the United States. METHODS: Univariate analysis and ordinal logistic regression were used to determine factors associated with an HBV DNA less than 100 IU/ml. RESULTS: The majority of patients were on HAART (85%), had an HIV RNA less than 50 copies/ml, a median CD4 cell count of 438 cells/microl, and had prior or current lamivudine therapy (98%). The majority (89%) of those on HAART were on HBV-active drugs including 54% on tenofovir (TDF) with either lamivudine (LAM) or emtrictabine (FTC), 34% receiving LAM or FTC monotherapy, and 12% on TDF monotherapy. Only 4% of patients in the combination (TDF + LAM/FTC) group had HBV DNA greater than 20 000 IU/ml compared to 54% in the group on no HBV-active therapy, 31% in the LAM or FTC monotherapy group, and 30% in the TDF monotherapy group (P < 0.0001). In an ordinal logistic regression model, monotherapy with either TDF or LAM remained independently associated with higher HBV DNA. CONCLUSION: These data suggest that there may be an advantage to using TDF in combination with LAM or FTC in HIV/HBV coinfection, particularly in the setting of previous LAM experience. Continued prospective follow-up in this study will confirm whether the advantage is sustained longer-term.
Authors: M Puoti; A Spinetti; A Ghezzi; F Donato; S Zaltron; V Putzolu; E Quiros-Roldan; B Zanini; S Casari; G Carosi Journal: J Acquir Immune Defic Syndr Date: 2000-07-01 Impact factor: 3.731
Authors: Kirsten L White; Nicolas A Margot; Terri Wrin; Christos J Petropoulos; Michael D Miller; Lisa K Naeger Journal: Antimicrob Agents Chemother Date: 2002-11 Impact factor: 5.191
Authors: Chloe L Thio; Eric C Seaberg; Richard Skolasky; John Phair; Barbara Visscher; Alvaro Muñoz; David L Thomas Journal: Lancet Date: 2002-12-14 Impact factor: 79.321
Authors: Kasha P Singh; Megan Crane; Jennifer Audsley; Anchalee Avihingsanon; Joe Sasadeusz; Sharon R Lewin Journal: AIDS Date: 2017-09-24 Impact factor: 4.177
Authors: Gail V Matthews; Eric C Seaberg; Anchalee Avihingsanon; Scott Bowden; Gregory J Dore; Sharon R Lewin; Joe Sasadeusz; Peter A Revill; Margaret Littlejohn; Jennifer F Hoy; Robert Finlayson; Kiat Ruxrungtham; Melissa Saulynas; Stephen Locarnini; Chloe L Thio Journal: Clin Infect Dis Date: 2013-01-11 Impact factor: 9.079
Authors: Kenneth C Kapembwa; Jason D Goldman; Shabir Lakhi; Yolan Banda; Kasonde Bowa; Sten H Vermund; Joseph Mulenga; David Chama; Benjamin H Chi Journal: J Glob Infect Dis Date: 2011-07
Authors: Mark H Kuniholm; Edgar Ong; Boris M Hogema; Marco Koppelman; Kathryn Anastos; Marion G Peters; Eric C Seaberg; Yue Chen; Kenrad E Nelson; Jeffrey M Linnen Journal: Hepatology Date: 2016-01-16 Impact factor: 17.425